MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT
Status:
Not yet recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
Allogeneic hematopoietic cell transplantation (Allo-HSCT) is an effective therapy for acute
leukemia, but relapse remains an important problem. Therapy options for relapse include
stopping immune suppression, re-induction of chemotherapy, donor lymphocyte infusion (DLI),
and another transplantation used alone or in combination. However, the efficacy of these
interventions is limited. One approach to the relapse problem is to intervene before
hematologic or pathologic relapse occurs based on minimal residual disease (MRD). In this
study, the efficacy of MRD-directed DLI on transplantation outcomes will be evaluated in
patients with acute leukemia receiving allo-HSCT.